Vertex will pay for the deal using a mix of cash and new debt. The company has lined up $4.5 billion in fully committed bridge financing from Bank of America (BAC) and Morgan Stanley (MS) to support the purchase.
Big Bet on Endocrine Diseases
Crinetics brings two major assets to Vertex. Its lead drug, Palsonify (paltusotine), is the first once‑daily oral therapy for acromegaly, a rare condition caused by excess growth hormone. The medicine won FDA approval in September 2025 and is under review in other markets. Since launch, Palsonify has seen strong early demand and wider insurance coverage, putting it on track to become a big‑selling drug.
Crinetics’ next most advanced program is atumelnant, a once‑daily oral drug now in Phase 3 for congenital adrenal hyperplasia (CAH), a serious genetic disease with few good treatment options. Early results show it can bring down high androgen levels while letting patients stay on normal steroid doses, a mix that could make it the top treatment for CAH.
Vertex Sees Major Long‑Term Revenue Potential
